$15.69 +0.08 (%) Nektar Therapeutics - NASDAQ

Dec. 19, 2014 | 03:59 PM

Partner Headlines

  1. Nektar Offers Data on Target-Specific Biomarkers from Circulating Tumor Cell Sub-Study of Phase 3 BEACON Study of NKTR-102

    Benzinga | Dec. 11, 2014 | 18:03PM EST
  2. Nektar Presents Positive Preclinical Data On Oral, Peripherally-Acting Kappa Agonist Molecules At 2014 American Academy Of Pain Management Meeting

    Benzinga | Sep. 19, 2014 | 09:01AM EST
  3. Progenics, Nektar Still Halted; FDA Advisory Committee Expected To Conclude Thursday

    Benzinga | Jun. 12, 2014 | 09:41AM EST
  4. Top Healthcare Movers For June 9, 2014

    Benzinga | Jun. 9, 2014 | 14:27PM EST
  5. Small Pharmaceuticals Rallying Following FDA Report

    Benzinga | Jun. 9, 2014 | 12:49PM EST
  6. Nektar Therapeutics Prices 8.5M Share Offering at $12.75/Share

    Benzinga | Jan. 22, 2014 | 22:50PM EST
  7. Nektar Therapeutics Announces Public Offering of 8.5M Shares of Common Stock

    Benzinga | Jan. 21, 2014 | 16:14PM EST
  8. Nektar Presents Positive Data from Phase 1 Study of Etirinotecan Pegol in Combination with 5-Flourouracil/Leucovorin at 2014 Gastrointestinal Cancers Symposium

    Benzinga | Jan. 18, 2014 | 12:34PM EST
  9. Etirinotecan Pegol Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer

    Benzinga | Jan. 14, 2014 | 08:18AM EST
  10. UPDATE: Piper Jaffray Initiates Coverage on Nektar Therapeutics on Expected Attractive Returns

    Benzinga | Nov. 27, 2013 | 10:53AM EST
  11. Nektar, Astra Zeneca Announce NDA for Naloxegol Accepted by FDA

    Benzinga | Nov. 19, 2013 | 07:07AM EST
  12. Market Wrap For November 8: Markets Erase Thursday's Losses; Dow Companies Dominate Headlines

    Benzinga | Nov. 8, 2013 | 16:57PM EST
  13. Nektar Reports on Advancements with Clinical Pipeline and Introduces New Preclinical Candidates at Investor and Analyst R&D Day

    Benzinga | Oct. 8, 2013 | 11:15AM EST
  14. Nektar Reports AstraZeneca Receives EMA Acceptance of Marketing Authorization Application for Naloxegol

    Benzinga | Sep. 30, 2013 | 05:41AM EST
  15. Market Wrap For Friday, September 27: Dow Ends The Week Negative For First Time In Month

    Benzinga | Sep. 27, 2013 | 16:29PM EST
  16. Mid-Afternoon Market Update: Cerner Rallies Major Contract While United Airlines Plummets

    Benzinga | Sep. 27, 2013 | 15:51PM EST
  17. Mid-Day Market Update: Finish Line Gains On Upbeat Results; JC Penney Shares Fall

    Benzinga | Sep. 27, 2013 | 12:44PM EST
  18. William Blair Reiterates Outperform Nektar Therapeutics Following NKTR-181 Phase 2 Trial Miss

    Benzinga | Sep. 27, 2013 | 11:14AM EST
  19. UPDATE: Brean Capital Lowers PT on Nektar Therapeutics Following NKTR-181 Phase 2 Trial Miss

    Benzinga | Sep. 27, 2013 | 11:14AM EST
  20. Mid-Morning Market Update: Markets Open Lower; BlackBerry Reports Q2 Loss

    Benzinga | Sep. 27, 2013 | 10:48AM EST
  21. Benzinga's Top Pre-Market Losers

    Benzinga | Sep. 27, 2013 | 08:12AM EST
  22. Nektar Says Results from Phase 2 Trial of NKTR-181 Missed Primary Efficacy Endpoint

    Benzinga | Sep. 26, 2013 | 16:11PM EST
  23. Market Wrap For Monday, August 12: Stocks Close Mixed To Start Week

    Benzinga | Aug. 12, 2013 | 16:42PM EST
  24. Mid-Afternoon Market Update: Silver Continues Strong Rally as Sarepta Remains Down

    Benzinga | Aug. 12, 2013 | 15:33PM EST
  25. Mid-Day Market Update: Markets Slump; Facebook Remains Up on Massive Volume

    Benzinga | Nov. 14, 2012 | 07:14AM EST
  26. UPDATE: Bank of America Lowers Nektar Therapeutics PO, Maintains Underperform

    Benzinga | Nov. 13, 2012 | 02:52AM EST
  27. Nektar Therapeutics Plunges on FDA Worries, Downgrade

    Benzinga | Nov. 12, 2012 | 08:42AM EST
  28. A Peek Into The Market Before The Trading Starts

    Benzinga | Nov. 12, 2012 | 00:17AM EST
  29. AstraZeneca Announces Positive Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation

    Benzinga | Nov. 11, 2012 | 23:39PM EST
  30. Stocks Hitting 52-Week Highs

    Benzinga | Sep. 27, 2012 | 04:08AM EST
  31. Nektar Therapeutics Says Got Positive Data from Phase 1a Study of NKTR-192

    Benzinga | Sep. 18, 2012 | 03:26AM EST
  32. Nektar Therapeutics Reports Operating Results (10-Q)

    GuruFocus | Aug. 9, 2012 | 13:33PM EST
  33. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181

    Benzinga | Jul. 24, 2012 | 02:01AM EST
  34. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181

    Benzinga | Jun. 7, 2012 | 02:05AM EST
  35. Top 4 Small-Cap Stocks In The Biotechnology Industry With The Highest Cash

    Benzinga | Jun. 3, 2012 | 21:39PM EST
  36. Morning Social Media Outlook for Thursday Mar 1 (CPRT, NKTR, RIMM, FNSR)

    Benzinga | Mar. 1, 2012 | 03:01AM EST
  37. Nektar Therapeutics (NKTR) Gains 11.5% On Sale of Drug Royalties

    MarketIntelligenceCenter | Feb. 29, 2012 | 13:39PM EST
  38. Nektar Therapeutics Reports Operating Results (10-K)

    GuruFocus | Feb. 29, 2012 | 10:25AM EST
  39. Nektar Therapeutics Up 7% After Selling Royalty Payment Agreements

    Benzinga | Feb. 29, 2012 | 08:13AM EST
  40. UPDATE: Bank of America Downgrades Nektar Therapeutics to Underperform, Maintains $6 PT

    Benzinga | Jan. 20, 2012 | 02:02AM EST
  41. Baxter Initiates Phase I Clinical Trial of Longer-Acting Recombinant FVIII Treatment for Hemophilia A

    Benzinga | Jan. 5, 2012 | 01:35AM EST
  42. Notable Call Options Activity on Nektar Therapeutics

    Benzinga | Dec. 28, 2011 | 06:08AM EST
  43. Nektar Reports Affymax Announced FDA Advisory Committee Voted in Favor of Benefit/Risk Profile for Peginesatide for Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis

    Benzinga | Dec. 8, 2011 | 01:23AM EST
Trading Center